Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Biovie Inc(BIVI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIVI
09/25/2026: BIVI (1-star) is currently NOT-A-BUY. Pass it for now.
BioVie Inc is a clinical-stage biotechnology company focused on developing therapies for Alzheimer's, Parkinson's, and liver-related diseases. The company's main strength lies in its specialized pipeline targeting high-unmet-need medical areas with innovative mechanisms of action. Its primary investment story centers on the potential for clinical trial success to unlock massive market opportunities, though this is balanced by high financial and execution risks. Investors should monitor clinical data readouts and regulatory engagement, as these are the main drivers for future valuation. Given its lack of revenue and high volatility, this stock is typically suited for speculative investors comfortable with the risks associated with biotechnology development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth play that requires successful clinical data to justify potential long-term value. |
| Momentum investor | Strong fit while signal remains positive | Biotech stocks like BIVI often experience significant price moves based on news flow and trial outcomes. |
| Value investor | Weak fit | BioVie lacks the earnings and revenue base necessary for traditional value investing frameworks. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on development. |
| Low-risk investor | Weak fit | The high volatility and clinical risk inherent in BIVI are unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are subject to sharp price fluctuations based on regulatory news and data. |
| Valuation risk | High | Valuations are highly speculative and depend entirely on future clinical and regulatory success. |
| Competition risk (Pharmaceutical competition) | High | Large incumbents possess significant advantages in resources and market reach. |
| Business quality | Medium | The company is a research-focused entity without commercial products or current cash flow. |
| Dividend income | Low / none | Income investors should not look to BIVI for yield. |
| Execution risk | High | Success depends on the complex and uncertain process of drug development and FDA approval. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -70.97% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.74M USD | Price to earnings Ratio - | 1Y Target Price 5.25 |
Price to earnings Ratio - | 1Y Target Price 5.25 | ||
Volume (30-day avg) 4.7M shares | Beta 0.74 | 52 Weeks Range 0.82 - 3.79 | Updated Date 09/25/2026 |
52 Weeks Range 0.82 - 3.79 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.05 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing BIV201 and NE3107 through the FDA pipeline. | The company is essentially betting on the success of its drug candidates in clinical trials. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5.25M | Price to Sales(TTM) - |
Enterprise Value 5.25M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.66 | Shares Outstanding 8.53M | Shares Floating 7.48M |
Shares Outstanding 8.53M | Shares Floating 7.48M | ||
Percent Insiders 0.53 | Percent Institutions 22.24 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Biovie Inc
Exchange NASDAQ | Headquarters Carson City, NV, United States | ||
IPO Launch date 2014-05-05 | President, CEO & Director Mr. Cuong Viet Do M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://bioviepharma.com |
Full time employees 13 | Website https://bioviepharma.com | ||
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.